Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
The Exosome Revolution is Here: 1 in 7 Publications Emerged in the Past Year
Exosomes have recently exploded in popularity, with companies developing exosome-based diagnostics, therapeutics, and cosmeceuticals. Although they were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. [Read more…]
Evia Bio® Announces Availability of GMP-Grade CellShield™ MSC DMSO-Free Cryopreservation Media
MINNEAPOLIS, MN – October 28th, 2026 – Evia Bio®, a leading provider of non-dimethyl sulfoxide (non-DMSO) cryopreservation solutions for the cell therapy and in vitro fertilization industries, today announced the GMP grade of CellShield™ cryopreservation media is now available for product shipment to customers.
The CellShield product line is DMSO-free and includes a controlled rate freezing program that optimizes viability, recovery and functionality. GMP grade CellShield MSC is now available for purchase via the Evia Bio website and direct shipment from the manufacturer. [Read more…]
The Little Known History of MSCs (Year-By-Year)
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immunoprivileged, making them an advantageous cell type for allogeneic transplantation. [Read more…]
China’s First Approved MSC Therapy, Ruibosheng, Hits the Market at a Fraction of Global Pricing
For years, the promise of mesenchymal stem cell (MSC) therapy has faced a stubborn barrier: cost. Even as regulators in South Korea, Japan, and other countries have cleared MSC-based products for commercial use, pricing for advanced cell therapies has often reached six figures, limiting access to a relatively small segment of patients and healthcare systems.
China’s first approved MSC therapy is challenging that assumption. Ruibosheng (amimestrocel injection), developed by Platinum Life Excellence Biotech, has entered the Chinese market at a price point that is a fraction of comparable cell therapies globally, highlighting how manufacturing innovation and scale may reshape the economics of regenerative medicine.
The National Medical Products Administration (NMPA) granted conditional approval to Ruibosheng on January 2, 2025, making it the first MSC-based cell therapy approved for market in China. The therapy was cleared for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) with predominant gastrointestinal involvement in patients aged 14 and older. Since receiving regulatory approval, Ruibosheng has progressed into commercial distribution and clinical adoption across Chinese hospitals. [Read more…]
- 1
- 2
- 3
- …
- 59
- Next Page »




